Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innate allogeneic hematopoietic stem cell transplantation with alpha/beta T-cell depletion and low-dose donor lymphocyte infusion
NL-OMON44165Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor lymphocytes in hematopoietic malignancies, leukemia, myelodysplastic syndrome (MDS) and 1 more, sponsored by University Medical Center Utrecht. Primary endpoint: Transplantation-related mortality within 100 days. Started Apr 2016; status: recruiting.
02
Drugs
donor lymphocytes
03
Conditions
hematopoietic malignanciesleukemiamyelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NL-OMON44165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44165.